Gynecologic Cancer Symposium Planning Committee:

- NJ Department of Health, Office of Cancer Control and Prevention
- NJ Department of Health, Cancer Education and Early Detection (NJCEED) Program
- Regional Chronic Disease Coalitions
  - Bergen and Hudson Counties
  - Burlington and Camden Counties
  - Cumberland, Gloucester and Salem Counties
  - Essex and Passaic Counties
  - Hunterdon and Mercer Counties
  - Middlesex and Union Counties
  - Monmouth and Ocean Counties
  - Morris and Somerset Counties
  - Sussex and Warren Counties
- Kaleidoscope of Hope Ovarian Cancer Foundation
- National Ovarian Cancer Coalition
- Teal Tea Foundation
- Visiting Nurse Association of Central Jersey
- Women of Teal Blog

Great appreciation is given to the planning committee for their expertise, countless hours of work and support in making this conference a success.

Please Visit Exhibitor Displays
Cancer Support Community of Central NJ | Capital Health Medical Center at Hopewell | Carol G. Simon Cancer Center, Atlantic Health System | Central Jersey Family Health Consortium | Fox Chase Cancer Center | Horizon Blue Cross Blue Shield of New Jersey | Horizon NJ Health | Kaleidoscope of Hope Ovarian Cancer Foundation | MD Anderson Cooper Center | National Ovarian Cancer Coalition | New Jersey State Department of Health Office of Cancer Control and Prevention & New Jersey Cancer Education and Early Detection | Rutgers Cancer Institute of New Jersey | Teal Tea Foundation

Gynecologic Cancer Symposium:

Striving for a Healthier Tomorrow, Today

Thursday, November 19, 2015

The Conference Center at Mercer College
West Windsor Township, NJ

Sponsored By
New Jersey Department of Health
Welcome to the Gynecologic Cancer Symposium:
Striving For a Healthier Tomorrow, Today

This Conference is designed for healthcare and public health professionals, gynecologic cancer survivors, caregivers and any interested members of the community. The conference will feature presentations on current gynecologic cancer practices, applied research and developments related to clinical practice and hospice and palliative care.

EVALUATIONS
- Pink Pre-Survey Form: Participants will complete the pink pre-survey forms which will be collected before and during the opening remarks. Late arrivers’ forms will be collected by designated symposium staff.
- Blue Post-Survey Form: Participants will complete the blue post-survey evaluations which will be collected at the end of the last breakout session. Please deposit blue evaluation forms in the bin located by each breakout room exit door or at the main conference center exit. If participants need to leave early, please return your completed form before you exit.

CREDITS
This activity has been submitted for approval to provide 5 CEU Credits. VNA of Central Jersey is an approved provider of continuing nursing education by the New Jersey State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

DISCLOSURE
The planners and presenters of this educational activity disclose no conflict of interest. There is no commercial support for this activity. Accredited status does not imply endorsement by The VNA of Central Jersey or ANCC of any commercial products or services.

From Research to Practice –
What’s New in Gynecologic Cancers?

David Warshal, MD
Vice-Chief, Department of Obstetrics & Gynecology at Cooper University
Division Head of Gynecologic Oncology
MD Anderson Cancer Center at Cooper

Dr. Warshal is the Vice-Chief of the Department of Obstetrics and Gynecology at Cooper University Health Care and Head of the Division of Gynecologic Oncology at MD Anderson Cancer Center at Cooper. Dr. Warshal is an Associate Professor of Obstetrics and Gynecology at Cooper Medical School of Rowan University. He has received several awards for excellence in teaching medical students and residents and was the 1999 recipient of the Humanism in Medicine Award from the Healthcare Foundation of New Jersey. Dr. Warshal has been named one of the regions “Top Doctors,” by publications such as Philadelphia Magazine, South Jersey and SJ magazines, and the Newark Star-Ledger among others.

Dr. Warshal serves as Cooper University Hospital’s Principal Investigator for the NRG – the new clinical and basic scientific research cooperative group funded by the National Cancer Institute (NCI) and chairs Cooper’s Institutional Review Board. He is active in the ongoing enhancement of New Jersey’s Comprehensive Cancer Control Plan. Dr. Warshal has authored more than 20 peer reviewed articles, multiple abstracts and four book chapters. Dr. Warshal is an active member of both regional professional organizations.
Patient Centered Communication and Approaches to Clinical Trial Enrollment

Nana Tchabo, MD
Associate Residency Director for Gynecology at Overlook Medical Center Women’s Cancer Center
Atlantic Health System Morristown and Overlook Medical Centers

Dr. Tchabo graduated from Brown University in 1996 with a Sc.B. in Neuroscience and a minor in Women’s Health. In 2000, she graduated from Brown University School of Medicine and was cited for academic excellence. She completed her residency in Obstetrics and Gynecology at Georgetown University in 2004. She received her fellowship training at the National Cancer Institute and completed her Gynecologic Oncology Fellowship Training in 2009 at Roswell Park Cancer Institute. She is a board certified Gynecologic Oncologist at Atlantic Center. She is a Principal Investigator on many of the Gynecologic Cancer Clinical Research Trials available at the Carol G. Simon Cancer Center. She also serves as Associate Residency Director for Gynecology at Overlook Medical Center.

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am - 9:00 am</td>
<td>Networking, Continental Breakfast, Conference Registration, Display Tables Please complete pink pre-survey forms, which will be collected before and during the opening remarks.</td>
</tr>
<tr>
<td>9:00 am - 9:15 am</td>
<td>Welcome and Introductions Robert S. DiPaola, MD Rutgers Cancer Institute of New Jersey</td>
</tr>
<tr>
<td>9:15 am - 9:30 am</td>
<td>Overview of Gynecologic Cancer in New Jersey Antoinette M. Stroup, Ph.D. New Jersey State Cancer Registry Rutgers School of Public Health Rutgers Cancer Institute of New Jersey</td>
</tr>
<tr>
<td>9:30 am - 10:20 am</td>
<td>From Research to Practice: What’s New in Gynecologic Cancers? David P. Warshal, MD MD Anderson Cancer Center at Cooper</td>
</tr>
<tr>
<td>10:20 am - 10:35 am</td>
<td>Break: Light Refreshments Served, Display Tables</td>
</tr>
<tr>
<td>10:35 am - 11:25 am</td>
<td>Cancer Prevention and Detection of Ovarian Cancer Lorna Rodriguez, MD, Ph.D. Rutgers Cancer Institute of New Jersey Robert Wood Johnson Medical School</td>
</tr>
<tr>
<td>11:25 am - 12:15 pm</td>
<td>Impact of Genetics Gina Mantia-Smaldone, MD Temple Fox Chase Cancer Center</td>
</tr>
<tr>
<td>12:15 pm - 1:15 pm</td>
<td>Buffet Lunch and Networking, Display Tables</td>
</tr>
</tbody>
</table>

Please visit Exhibitor Displays from 8 am to 3 pm
### Breakout Session I

**1:15 pm - 2:15 pm**  
**Rm 122 RED**  
**The Impact of GYN Cancer on Sexuality and Intimacy**  
Amy Harvey O’Keeffe, MD  
Center for Women’s’ Health

**Rm 213 BLUE**  
**Risk Assessment and Management for Ovarian & Uterine Cancer**  
Rachel Rando, MS, CGC  
Hunterdon Regional Cancer Center

**Rm 116 YELLOW**  
**Patient Centered Communication to Clinical Trial Enrollment**  
Nana Tchabo, MD  
Atlantic System Morristown and Overlook Medical Center

**Rm 214 GREEN**  
**Panel Discussion: Voices of Women Cancer Survivors**  
Moderator: Lynn Franklin, Kaleidoscope of Hope

### Breakout Session II

**2:15 pm – 3:30 pm**  
**Rm 122 RED**  
**Psychological Impact of Gynecologic Cancers: Therapeutic Interventions**  
Sharon L. Manne, Ph.D.  
Rutgers Cancer Institute of New Jersey

**Rm 116 YELLOW**  
**Palliative and Hospice Care**  
Darlene G. Gibbon, MD  
Rutgers Cancer Institute of New Jersey

**Rm 213 BLUE**  
**Immunotherapy: Diagnosis & Treatment of Gynecologic Cancers**  
Gina Mantia-Smaldone, MD  
Temple Fox Chase Cancer Center

**Rm 171 GREEN**  
**Jin Shin Jyutsu: Harmonizing Your Life Energy**  
Meg McQuarrie  
Elixir Fund

---

* Those seeking Continuing Education Unit (CEU) Credits may not elect Jin Shin Jyutsu as a breakout session.

---

**Overview of Gynecologic Cancer in New Jersey**

Antoinette M. Stroup, Ph.D.  
Director of New Jersey State Cancer Registry  
Associate Professor and Division Chief of Cancer Epidemiology  
Rutgers School of Public Health  
Rutgers Cancer Institute of New Jersey

Dr. Antoinette Stroup is the Director of the New Jersey State Cancer Registry, an Associate Professor and Division Chief of Cancer Epidemiology at the Rutgers School of Public Health and a Resident member of the Rutgers Cancer Institute of New Jersey. She received her Ph.D. in Epidemiology from the University of California, Berkeley and has been a member of the cancer surveillance community for nearly 15 years. Her primary research interests are in cancer surveillance research and cancer disparities.

---

Please complete the blue post-survey forms at end of Breakout Session II
Cancer Prevention and Detection of Ovarian Cancer

Lorna Rodriguez, MD, Ph.D.
Director of Precision Medicine
Rutgers Cancer Institute of New Jersey
Professor of Obstetrics and Reproductive Sciences at Robert Wood Johnson Medical School

Lorna Rodriguez, MD, Ph.D. is leading the Precision Medicine Initiative at the Rutgers Cancer Institute of New Jersey. She is the Director of Precision Medicine and a Professor in the Department of Obstetrics and Gynecology at Rutgers Robert Wood Johnson Medical School. She was an Assistant Professor at the Albert Einstein College of Medicine in New York and the Director of Gynecologic Oncology at the University of Rochester, NY before moving to New Jersey. Once in New Jersey, she served as the Chief of Gynecologic Oncology at the Rutgers Cancer Institute of New Jersey from September 2000 – June 2012 and has been the Director of the Precision Medicine Initiative since July, 2012. A graduate of the University of Puerto Rico Medical School, Dr. Rodriguez completed her fellowship in Gynecologic Oncology at the University of Michigan, her residency at Cooper Hospital University Medical Center, Camden, New Jersey and earned a Ph.D. in biochemistry from the University of Rochester. Dr. Rodriguez has published many articles in peer reviewed journals as well as book chapters and presents regularly at national and international professional meetings. Her laboratory discoveries include the identification of the role of the CD44 receptor in multidrug resistance. As a clinician and scientific investigator, she conducts extensive research to translate findings into today’s cancer treatments.

Welcome and Introductions

Robert S. DiPaola, MD
Director
Rutgers Cancer Institute of New Jersey

As Director, Dr. DiPaola is responsible for research activities and administrative oversight of the Rutgers Cancer Institute of New Jersey, New Jersey’s National Cancer Institute (NCI)-designated Comprehensive Cancer Center. Dr. DiPaola has held multiple local and national positions and has considerable experience in translational research focused on the study of prostate cancer and drug resistance locally and nationally. His accomplishments in the area of translational research are underscored by grants from the National Institutes of Health (NIH), Department of Defense, and private foundations, as well as his publications in prominent journals including the New England Journal of Medicine, JAMA, Cell, Clinical Cancer Research, and the Journal of Clinical Oncology. Working with the State of New Jersey, Dr. DiPaola led the Cancer Institute through a successful integration with Rutgers, which now benefits Rutgers CINJ through a large university matrix. Nationally, as Chairman of the Genitourinary (GU) Committee of the Eastern Cooperative Oncology Group (ECOG) for a term from 2004 until 2011, he led the committee through two NCI reviews and launched multiple national phase III studies including a study of chemo-hormonal therapy reported in 2014 that now supports a new standard of care in prostate cancer published last month in the New England Journal of Medicine. He is on many national committees including currently serving as a full member of the National Cancer Institute’s subcommittee A (parent committee) for Cancer Center reviews, and was the 2014 Chair for the American Society of Clinical Oncology’s GU program committee and 2014 program Chair for the Association of American Cancer Institute’s annual meeting.
Palliative and Hospice Care

**Darlene G. Gibbon, MD**  
Chief of Gynecologic Oncology and Reproductive Medicine  
Rutgers Cancer Institute of New Jersey

Dr. Darlene Gibbon is Associate Professor of Obstetrics, Gynecology and Reproductive Medicine and Chief of Gynecologic Oncology at the Rutgers Cancer Institute of New Jersey, Rutgers – Robert Wood Johnson Medical School. Dr. Gibbon is Board Certified in Gynecologic Oncology and Obstetrics/Gynecology. She is one of a limited number of gynecologic oncologists in the country who is board certified in Hospice and Palliative Care Medicine. In addition to maintaining a busy clinical practice incorporating participation on clinical trials with the surgical and medical care of women diagnosed with a gynecologic malignancy, Dr. Gibbon incorporates palliative techniques to improve her patient’s quality of life. Dr. Gibbon has been recognized for her commitment to patient care. She has received numerous awards including the 2009 Cancer Institute’s “Leadership in Patient Care Award”, the 2013 Union County Women of Excellence in Medicine award, the Morris Glass, MD ‘25 Master Teacher Award in Gynecologic Oncology by the Alumni Association of the State University of New York Downstate Medical Center, as well as being named a Top Doctor in New Jersey by New Jersey Magazine on numerous occasions. Her research interests have focused on clinical research, in particular Phase I clinical trial development and translational research endeavors for women diagnosed with a gynecologic malignancy with a focus on ovarian cancer.

Risk Assessment and Management for Ovarian & Uterine Cancer

**Rachel Rando, MS, CGC**  
Family Risk Assessment Program  
Hunterdon Regional Cancer Center

Rachel Rando received a Master’s degree in Genetic Counseling from the University of Pittsburgh, and is certified in genetic counseling by the American Board of Medical Genetics. She worked in prenatal and pediatric genetics and was an instructor and coordinator of a March of Dimes course in genetics for allied health professionals. She received intensive training in cancer genetics from Fox Chase Cancer Center and City of Hope Cancer Center in California. Ms. Rando has provided genetic counseling at Hunterdon Regional Cancer Center since 2007, and is an active member of the City of Hope cancer genetics research network and of the National Society of Genetic Counselors (NSGC). She was the recipient of a grant from the NSGC Cancer Special Interest Group which was used to develop a patient resource to assist parents when discussing a familial BRCA mutation with their children. Rachel serves as supervisor during clinical internships for genetic counseling graduate students. She has given presentations on cancer genetics and cancer risk assessment at the local, state and national levels, including community education programs, radio and television programs, hospital Grand Rounds, a national oncology symposium, and a national webinar.
Impact of Genetics

Gina Mantia-Smaldone, MD  
Attending Surgeon for Department of Surgical Oncology  
Temple Fox Chase Cancer Center

Dr. Mantia-Smaldone is a Gynecologic Oncologist within the Department of Surgical Oncology at Fox Chase Cancer Center in Philadelphia. After receiving her medical degree from the State University of New York at Stony Brook School of Medicine, Dr. Mantia Smaldone completed a residency in Obstetrics and Gynecology at Magee-Women’s Hospital of the University of Pittsburgh Medical Center. She then completed a postdoctoral fellowship in ovarian cancer immunology within the division of gynecologic oncology at Magee-Women’s Research Institute of the University of Pittsburgh. She completed her fellowship training in Gynecologic Oncology at the Hospital of the University of Pennsylvania before coming to Fox Chase Cancer Center. Dr. Mantia-Smaldone’s research interests include the development of innovative therapeutics for ovarian cancer patients, BRCA mutations and hereditary ovarian cancer, and fertility and gynecologic cancers.

Jin Shin Jyutsu: Harmonizing Your Life Energy

Meg McQuarrie
Founder and Executive Director
Elixir Fund

Meg McQuarrie is the Founder and Executive Director of the Elixir Fund, a non-profit organization that is dedicated to improving the comfort and care of cancer patients and their caregivers. The goal of Elixir Fund’s programs is to provide patients and caregivers with a break from cancer so that they may live a full and rich life during treatment and beyond. Elixir Fund’s Bridges to Wellness program provides experiential introduction to complementary therapies, such as yoga, meditation, tai chi and other modalities that have been shown to decrease stress, and aid in the relief of symptoms and side effects related to treatment. Meg will be offering sessions in meditation and Jin Shin Jyutsu - a simple form of acupressure that can used to reduce stress, manage pain and nausea, aid in sleeplessness and much more.
The Impact of GYN Cancer on Sexuality and Intimacy

Amy Harvey O’Keeffe, MD
Center for Women’s Health in Langhorne, PA

Recognized by Philadelphia Magazine as a Top Doc in the Greater Philadelphia area, Dr. Amy Harvey O’Keeffe is a Board Certified Gynecologist and Obstetrician who specializes in menopausal medicine and women’s sexual health. She received her medical degree from Temple University School of Medicine in Philadelphia, PA, where she also completed her residency in Gynecology and Obstetrics. She is in private practice at the Center for Women’s Health in Langhorne, PA holds an attending hospital staff position with St. Mary’s Medical Center in Langhorne, PA, and with Capital Health Medical Center in Hopewell, NJ. She speaks both locally and internationally on women’s health topics and has served as a Co-Medical Director for medical missions to the Dominican Republic for nine years. Additionally, she established a cancer support group for women with gynecological cancers, The GyniGirls, and is an Advisory Board member for The Teal Tea Foundation for Ovarian Cancer. Dr. Harvey O’Keeffe brings love and compassion to her work as a healer.

Psychological Impact of Gynecologic Cancers: Therapeutic Interventions

Sharon L. Manne, Ph.D.
Chief of Population Science
Associate Director for Cancer Prevention and Control
Rutgers Cancer Institute of New Jersey

Dr. Manne is a tenured Professor, Chief of Population Science, and Associate Director for Cancer Prevention and Control at Rutgers Cancer Institute of New Jersey. She is an internationally-recognized researcher with extensive experience in observational and interventional research on quality of life issues in people with cancer. With over 25 years of research experience, she is a leading expert in behavioral oncology. Dr. Manne is an innovative and creative scientist who is very passionate about her research. She was trained as a clinical psychologist and her research has merged social, clinical, and health psychology, and used a family systems-based orientation to help understand and reduce the adverse psychosocial impact of serious illness on patients and their families. Her track record of impactful research and grant funding is impressive and demonstrates her recognition as a leader in cancer behavioral medicine and psycho-oncology. She has over 150 peer-reviewed publications and has served as the principal investigator on 14 federally-funded grants. Her broad ranging research spans from studying the impact of cancer on quality of life of patients and their families, to examining factors that predict long-term psychological adaptation following cancer diagnosis and treatment, to developing and testing behavioral interventions to reduce the negative impact of cancer on patients and their families, and promoting cancer prevention screening among high risk individuals.